ViroPharma falls, stops developing hepatitis drug
Shares of ViroPharma Inc. (Nasdaq:VPHM) are sagging on news after the close on Wednesday that the Exton, Pa.-based company has cancelled the development of a drug for the treatment of hepatitis C due to safety issues from ongoing clinical trials with sick patients.
“Clearly, this is a disappointing outcome for patients suffering from this difficult disease,” CEO Vincent Milano said in a statement. “However, the risk associated with potential hepatotoxicity ultimately posed too high of a hurdle to merit further development.”
Hepatitis C is a blood-borne disease that can cause liver inflammation and cirrhosis.
At 2:11 p.m. ET, the stock was off $0.36, or 4%, to $9.26.
“Clearly, this is a disappointing outcome for patients suffering from this difficult disease,” CEO Vincent Milano said in a statement. “However, the risk associated with potential hepatotoxicity ultimately posed too high of a hurdle to merit further development.”
Hepatitis C is a blood-borne disease that can cause liver inflammation and cirrhosis.
At 2:11 p.m. ET, the stock was off $0.36, or 4%, to $9.26.
For access to the full article, you must be a registered member - it's FREE.
Already a member? Please log in below
Not Registered?
Register today and enjoy all that SmallCapInvestor.com has to offer, including:
- Daily small cap stock profiles.
- Intra-day coverage of Russell 2000 companies.
- Research and insights from our analysts.
- Special reports.
